TRAVERE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
TRAVERE THERAPEUTICS, INC. (TVTX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value of $186.92 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 · last filed 2026-08-04
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $186.92M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $54.06M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $30.02M.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $4.53M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value |
|---|---|
| 2026-06-30 | $186.92M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $54.06M 10-Q · filed 2026-05-04 |
| 2025-09-30 | $30.02M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $4.53M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $7.35M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $3.25M 10-K · filed 2025-02-21 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-21 |
| 2022-12-31 | $21.81M 10-K · filed 2025-02-21 |
| 2021-12-31 | $71.06M 10-K · filed 2024-02-20 |
| 2020-12-31 | $46.63M 10-K · filed 2023-02-23 |
| 2019-12-31 | $4.49M 10-K · filed 2022-02-24 |
| 2018-12-31 | $35.39M 10-K · filed 2021-03-01 |
| 2017-12-31 | $31.99M 10-K · filed 2019-02-26 |
| 2016-12-31 | $23.36M 10-K · filed 2019-02-26 |
| 2014-06-30 | $1.81M 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |